The recommendations for ibuprofen also apply to dexibuprofen, a high dose of which is defined as ≥1,200 mg per day. Product information for ibuprofen- and dexibuprofen-containing medicines will be updated to take into account advice on the cardiovascular risk associated with high-dose treatment – this will be implemented by the Member States where the medicines are authorised, according to an agreed timetable. Product information will also be updated to take into account the interaction between ibuprofen and low-dose aspirin.